Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart failure. OM was reported to increase left ventricular ejection fraction and systolic ejection time, but little is known about the effect of heart rate on the action of OM. The present study, therefore, was designed to investigate the effects of OM on unloaded cell shortening and intracellular Ca2+ ([Ca2+]i) transients as a function of the pacing frequency. Isolated cardiomyocytes were stimulated at various frequencies under steady-state conditions. Cell length was monitored by an optical edge detector and changes in [Ca2+]i were followed using the Ca2+-sensitive dye Fura-2. At the pacing frequency of 1 Hz, OM (1–10 μM) significantly decreased both diast...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardi...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
Due to the limited results achieved in the clinical treatment of heart failure, a new inotropic stra...
Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second d...
Background Many patients with heart failure remain symptomatic and have a poor prognosis despite exi...
Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance ...
Heart failure became a leading cause of mortality in the past decades with a progressively increasin...
BACKGROUND: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function...
Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function i...
Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic th...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardi...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
Due to the limited results achieved in the clinical treatment of heart failure, a new inotropic stra...
Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second d...
Background Many patients with heart failure remain symptomatic and have a poor prognosis despite exi...
Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance ...
Heart failure became a leading cause of mortality in the past decades with a progressively increasin...
BACKGROUND: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite ex...
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function...
Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function i...
Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic th...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...
BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardi...
Introduction: Current available inotropic agents increase cardiac contractility, but are associated ...